ALXO Key Statistics, Chart & Performance
The current stock price of ALXO is 1.33 USD. In the past month the price decreased by -3.62%. In the past year, price decreased by -17.9%.
ALXO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ALXO
Company Profile
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 44 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Company Info
ALX ONCOLOGY HOLDINGS INC
323 Allerton Avenue
South San Francisco CALIFORNIA 94010 US
CEO: Jaume Pons
Employees: 44
Phone: 16504667125
ALX ONCOLOGY HOLDINGS INC / ALXO FAQ
What does ALXO do?
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 44 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
What is the stock price of ALX ONCOLOGY HOLDINGS INC today?
The current stock price of ALXO is 1.33 USD. The price decreased by -2.21% in the last trading session.
Does ALX ONCOLOGY HOLDINGS INC pay dividends?
ALXO does not pay a dividend.
How is the ChartMill rating for ALX ONCOLOGY HOLDINGS INC?
ALXO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for ALXO stock?
ALX ONCOLOGY HOLDINGS INC (ALXO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.97).
When does ALX ONCOLOGY HOLDINGS INC (ALXO) report earnings?
ALX ONCOLOGY HOLDINGS INC (ALXO) will report earnings on 2026-03-04, after the market close.
What is the Short Interest ratio of ALX ONCOLOGY HOLDINGS INC (ALXO) stock?
The outstanding short interest for ALX ONCOLOGY HOLDINGS INC (ALXO) is 1.84% of its float.
ALXO Technical Analysis
ALXO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALXO. Both the profitability and financial health of ALXO have multiple concerns.
ALXO Financial Highlights
Over the last trailing twelve months ALXO reported a non-GAAP Earnings per Share(EPS) of -1.97. The EPS increased by 33.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -130.57% | ||
| ROE | -241.09% | ||
| Debt/Equity | 0.15 |
ALXO Forecast & Estimates
11 analysts have analysed ALXO and the average price target is 3.06 USD. This implies a price increase of 130.08% is expected in the next year compared to the current price of 1.33.